Polymerase Chain Reaction (PCR) Market Growth in Oncology, Pathogen Detection, and Forensics
Polymerase Chain Reaction (PCR) Market Growth in Oncology, Pathogen Detection, and Forensics
Polymerase Chain Reaction (PCR) market continues to expand as this widely-used molecular diagnostic tool plays a critical role across various sectors, including healthcare, research, pharmaceuticals, forensics, and food safety. PCR technology enables rapid amplification and detection of DNA and RNA, making it essential for accurate disease diagnosis, genetic testing, and scientific research.
According to Fortune Business Insights, the polymerase chain reaction (PCR) market was valued at USD 9.15 billion in 2023 and is projected to grow from USD 9.91 billion in 2024 to USD 19.23 billion by 2032, exhibiting a CAGR of 8.6% during the forecast period. In 2023, North America dominated the PCR market with a market share of 40%.
Bio-Rad Laboratories, Inc. (California, U.S.)
QIAGEN (Hilden, Germany)
Hoffmann-La Roche Ltd (Basel, Switzerland)
Agilent Technologies, Inc. (California, U.S.)
Abbott (Illinois, U.S.)
Eppendorf AG (Hamburg, Germany)
Sysmex Inostics (Hyogo, Japan)
Thermo Fisher Scientific Inc. (Massachusetts, U.S.)
BD (New Jersey, U.S.)
A key trend reshaping the PCR landscape is the shift from traditional real-time PCR (qPCR) toward more precise digital PCR technologies. While qPCR remains widely used, limitations such as quantification accuracy have driven demand for digital PCR, which provides absolute quantification, higher sensitivity, and better reproducibility
In November 2023, Stilla Technologies launched the Nio+ digital PCR system—capable of multiplex analysis using seven fluorescent channels, demonstrating the speed of innovation within the industry
Similarly, key players such as Bio-Rad furthered the technology through the release of new innovative platforms like the QX ONE Droplet Digital PCR system, tailored for drug development and high-precision diagnostic applications
Several factors are fueling this expansion:
Rising prevalence of infectious diseases: Conditions such as COVID-19, tuberculosis, influenza, HIV, and hepatitis have increased the demand for rapid, accurate diagnostics. PCR remains the gold-standard in molecular diagnostics for such pathogens
Expansion in oncology and genetic testing: PCR serves a critical role in detecting genetic mutations and monitoring cancer-related biomarkers, supporting its adoption in personalized medicine
Increased R&D and forensic applications: Growing investment in molecular biology, genetic engineering, forensic science, and new drug development is driving reagent and instrument sales
COVID-19 demand surge: The global pandemic massively increased PCR testing volumes and highlighted the need for large-scale production of PCR instruments, reagents, and assays
Real-Time PCR (qPCR): Dominated the market in 2023, driven by its established role in infectious disease testing and diagnostic labs
Digital PCR: Gaining momentum; considered the fastest-growing segment due to its advantages in precision and sensitivity
Standard PCR: Continues to serve fundamental research and laboratory functions, though overshadowed by advanced variants.
Reagents & Consumables: Held the largest share, propelled by consistent demand in test processing, high volumes during pandemics, and continuous assay development
Instruments: Growing steadily; demand from diagnostic centers, academic labs, and pharmaceutical R&D drives capital expenditure
Infectious Diseases: The largest segment, with PCR the gold standard for detecting pathogens like SARS-CoV-2 and Mycobacterium tuberculosis
Oncology: DNA-based mutation detection and liquid biopsies continue to foster growth.
Genetic Disorders: PCR remains vital for pre-natal testing and hereditary disease screening.
Other Applications: Include forensics, transplantation monitoring, and environmental testing.
Diagnostic Centers: The leading end-user, benefiting from high test throughput and quick turnaround demands
Hospitals & Clinics: Significant demand for routine testing and integrated clinical workflows.
Pharmaceutical & Biotech Industries: Utilize PCR in drug development, quality control, and RNA-based product assays.
Academic & Research Institutions: Continued use in basic science and molecular biology research.
Explore the full research report with detailed insights and TOC:https://www.fortunebusinessinsights.com/polymerase-chain-reaction-pcr-market-102528
North America: The dominant region with revenues of ~USD 3.66 billion in 2023 (≈40% share), driven by strong healthcare infrastructure, incentive-driven reimbursement policies, and high public awareness
Europe: The second-largest market, buoyed by regulations, healthcare investment, and growing chronic diseases requiring molecular diagnostics
Asia-Pacific: Set to grow at the fastest CAGR during the forecast period, propelled by rising healthcare infrastructure in China, India, Japan, and Southeast Asia
The PCR market’s future is bright:
Digital PCR Gains: Expected to expand rapidly by offering precise, multiplexed quantification, and detection of rare targets. Nio+ and Bio-Rad’s QX ONE highlight key strides
Point-of-Care Innovations: Portable, faster PCR tools are under development to democratize testing access globally.
Integration with AI and Automation: Future systems will leverage machine learning to reduce errors, optimize protocols, and speed up workflows.
Expanded Applications: PCR’s role in oncology monitoring, pharmacogenetics, agricultural biotech, and environmental testing will grow significantly.
Emerging Market Uptake: Asia-Pacific regions will continue to adopt PCR technologies as health infrastructure awareness increases.
About Us:
Fortune Business Insights provides expert corporate analysis and accurate data, enabling businesses of all sizes to make timely decisions. We offer customized solutions tailored to each client’s needs, helping them address unique challenges. Our goal is to empower clients with holistic market intelligence and offer granular insights into the market they operate in.
Our reports are a blend of quantitative and qualitative analysis, aimed at helping businesses achieve sustainable growth. Our experienced analysts and consultants use leading research methodologies to provide comprehensive market assessments enriched with relevant data.
At Fortune Business Insights, we aim to highlight growth opportunities for our clients, offering insights and recommendations that help them navigate technological and market changes. Our consulting services are designed to help companies uncover hidden opportunities and address competitive challenges.
Contact us:
Fortune Business Insights™ Pvt.
Phone: USA: +1 833 909 2966 (Toll-Free),
United Kingdom: +44 808 502 0280 (Toll-Free),
APAC: +91 744 740 1245
Email: sales@fortunebusinessinsights.com